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Abstract
Background: Tuberculosis (TB) in migrants is an ongoing challenge in several low TB incidence countries since a
large proportion of TB in these countries occurs in migrants from high incidence countries. To meet these
challenges, several countries utilize TB screening programs. The programs attempt to identify and treat those with
active and/or infectious stages of the disease. In addition, screening is used to identify and manage those with
latent or inactive disease after arrival. Between nations, considerable variation exists in the methods used in
migration-associated TB screening. The present study aimed to compare the TB immigration medical examination
requirements in selected countries of high immigration and low TB incidence rates.
Methods: Descriptive study of immigration TB screening programs
Results: 16 out of 18 eligible countries responded to the written standardized survey and phone interview. Comparisons
in specific areas of TB immigration screening programs included authorities responsible for TB screening, the primary
objectives of the TB screening program, the yield of detection of active TB disease, screening details and aspects of follow
up for inactive pulmonary TB. No two countries had the same approach to TB screening among migrants. Important
differences, common practices, common problems, evidence or lack of evidence for program specifics were noted.
Conclusions: In spite of common goals, there is great diversity in the processes and practices designed to
mitigate the impact of migration-associated TB among nations that screen migrants for the disease. The long-term
goal in decreasing migration-related introduction of TB from high to low incidence countries remains diminishing
the prevalence of the disease in those high incidence locations. In the meantime, existing or planned migration
screening programs for TB can be made more efficient and evidenced based. Cooperation among countries doing
research in the areas outlined in this study should facilitate the development of improved screening programs.
Background
Medical screening related to the process of immigration
commonly includes screening for tuberculosis (TB). The
intent and rationale of the process is to diagnose and
treat active, infectious TB before arrival, or as soon as
possible after arrival, in order to prevent transmission to
persons in the host country. Secondary benefits of
immigration screening are reduced transmission of TB
in the country of origin and during travel. Growing inci-
dence of multi drug resistant (MDR) and even exten-
sively drug resistant (XDR) TB in some regions of the
world underscore the importance for screening of
migrants. Screening for TB among migrant populations
has been shown to lead to earlier detection of cases,
resulting in a shorter duration of symptoms, and fewer
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of infectiousness by as much as 33% in some situations
[1]. Additionally, the identification of those with inactive
pulmonary TB (PTB) or latent TB infection (LTBI) pro-
vides opportunity for early treatment and the prevention
of significant health sequelae for the individual. In spite
of their benefits, TB immigration screening programs
are subject to many shortcomings. It has been suggested
that pre-departure screening detects only a small num-
ber of active cases [2,3], which is the primary objective
of most programs. Some have contended that very few
active infectious cases are identified [4] due in part to
the screening tools used and programmatic challenges
faced within immigration TB screening programs.
The chest radiograph (CXR) has been and remains the
central tool in screening for TB among migrants in
most programs. However the CXR’s sensitivity and spe-
cificity for the diagnosis of active pulmonary TB is only
in the range of 64-80% and 52-63% respectively [5-8]
and is thus not the gold standard. The CXR alone has
been reported to have a low negative predictive value
for the identification of active TB in migrants [9]. Using
estimates from the literature one group estimated that
t h ep o s i t i v ep r e d i c t i v ev a l u eo ft h eC X Rw a sl e s st h a n
1% assuming a prevalence of active disease of 1% [10].
Thus reliance on CXR leads to many false positive
results, unnecessary further testing, and follow up. This
finding is supported by another recent study [11]. On
the other hand, radiographic screening has demon-
strated benefits in screening large numbers of indivi-
duals in high prevalence populations where the
background level of disease may be higher [12].
The other major component of immigration-related TB
screening is the referral for evaluation and possible treat-
ment for individuals determined to have inactive PTB or
LTBI detected during screening. Known by a variety of
descriptions such as “post-arrival screening”, “medical
surveillance” or a “health undertaking,” compliance with
this screening component determines its effectiveness.
A Canadian study [13] determined that 14% of foreign-
born patients developing active PTB after arrival had
been noted to have inactive PTB during their immigra-
tion medical examination. However, only 20% of patients
were examined after arrival and adhered to treatment.
More recent studies have indicated that an average of
50% of such individuals are now completing post-
immigration medical surveillance requirements in
Canada [14].
Concerns regarding the benefits and costs of immigra-
tion screening for TB have raised suggestions that there
may be alternative, more effective means of dealing with
TB resulting from immigration. It has been demonstrated
that the risk of TB transmission to host populations from
migrants is in fact low [15-17]. For this reason, some sug-
gest the use of contact tracing of active cases in migrants
as a more efficient and cost effective way [18] of mana-
ging TB among the immigrant population as opposed to
routine immigrant TB screening [19].
The lack of robust evidence for TB immigration
screening and significant operational problems encoun-
tered by programs [13,18] may in part explain the signif-
icant variation among national TB immigration
screening programs. Some nations utilize pre-departure
screening, such as Australia, Canada and the United
States of America (U.S.), where international immigra-
tion represents a longstanding national policy for nation
building. Other nations where large-scale immigration
represents a newer social process have different prac-
tices. In one study [20], 13 (50%) of 26 European coun-
tries did not have any specific TB screening program for
migrants. All of the countries that had programs princi-
pally screened refugees and asylum seekers, (known as
refugee claimants in some countries). None did pre-
departure screening; 3 screened at the port of entry and
9 in reception or holding centers. No two European
countries took the same approach to screening. Similar
diversity in practices was noted by another study [21]
examining the service model delivery system of screen-
ing. The present study was designed to compare certain
aspects of established national TB immigration screen-
ing programs of selected high immigration low inci-
dence TB countries. Gaps in knowledge were identified
to help direct future research in the field.
Methods
Country selection
Country selection was based on the following criteria
(Table 1):
1) One of the 20 countries accepting the most immi-
grants based on the United Nations’ World Migration
2005 Report (published every 5 years) [22] OR
2) Immigration medical TB screening results pub-
lished in any peer-reviewed journal AND
3) A low domestic TB incidence rate defined as a rate
of sputum smear positive PTB of < 15 cases per 100,000
population as estimated by the World Health Organiza-
tion (WHO) averaged over the years 2004, 2005 and
2006 [14].
The survey
The survey was completed during the months of July and
August 2008. Country specific details reported in this
document were accurate as of April 2009 and for the US
October 2009. Variables included immigration-associated
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mary objectives of the TB screening program, the yield of
TB detection, operational aspects and requirements of
pre departure and post arrival screening for medical or
public health follow up for inactive PTB or LTBI. The
information collected was focused on established national
policies and guidelines rather than individual clinic pro-
cedures within nations and is publically available.
Statistics
Stata version 10 (Statacorp, College Station, Texas,
USA) software was used to calculate differences between
incidence rates of TB between countries using the
unpaired t-test.
Results
Participation in the study
Of 18 countries initially selected 16 (89%) participated
in the study. This included 11 of 12 countries selected
on the basis of high foreign-born populations and low
domestic TB incidence. Of six countries chosen for the
study on the basis of publications regarding their TB
immigration screening programs, five responded. All
participating countries are listed in Table 2.
Table 1 High immigration countries with respective incidences of all forms of TB and smear positive active pulmonary
TB (PTB)
Country % contribution
to world
migration
2005*
(in millions)†
All forms of TB incidence rate
per 100,000 reported in 2006§
(absolute number of cases)
Smear positive PTB† incidence
rate per 100,000 reported in
2006§ (absolute number of cases)
WHO 3 year estimate
average sputum positive
smear PTB incidence rate
per
100,000
Included
in survey
United
States
20.2 (38.4) 4 (13,148) 2 (5,777) 2 Yes
Russian
Fed
6.4 (12.1) 107 (152,797) 48 (68,178) 51 No
Germany 5.3 (10.1) 6 (5,370) 3 (2,407) 3 Yes
Ukraine 3.6 (6.8) 106 (49,308) 47 (21,902) 45 No
France 3.4 (6.5) 14 (8,630) 6 (3,830) 6 Yes
Saudi
Arabia
3.3 (6.4) 44 (10,631) 20 (4,784) 19 No
Canada 3.2 (6.1) 5 (1,678) 2 (748) 2 Yes
India 3.0 (5.7) 168 (1,932,852) 75 (867,455) 75 No
United
Kingdom
2.8 (5.4) 15 (9,358) 7 (4,177) 6 Yes
Spain 2.5 (4.8) 30 (13,179) 13 (5,810) 12 Yes
Australia 2.2 (4.1) 6 (1,329) 3 (595) 3 Yes
Pakistan 1.7 (3.3) 181 (291,743) 82 (131,192) 82 No
UAE
(United
Arab
Emirates)
1.7 (3.2) 16 (681) 7 (306) 7 Yes
Hong
Kong, SAR
China
1.6 (3.0) 62 (4,433) 28 (1,995) 32 No
Israel 1.4 (2.7) 8 (521) 3 (233) 3 Yes
Italy 1.3 (2.5) 7 (4,393) 3 (1,945) 3 Yes
Kazakhstan 1.3 (2.5) 130 (19,961) 59 (8,971) 64 No
Cote
d’Ivoire
1.2 (2.4) 420 (79,515) 183 (34,669) 173 No
Jordan 1.2 (2.2) 5 (306) 2 (138) 2 Yes
Japan 1.1 (2.0) 22 (28,330) 10 (12,736) 12 Yes
*United Nations, Trends in total migrant stock: The 2005 revision[22]
†The number of international migrants, also called the international migrant stock, generally represents the number of persons born in a country other than that
in which they live.
‡ PTB - pulmonary TB
§ World Health Organization, Tuberculosis Control, Surveillance, Planning and Finances[54].
Alvarez et al. BMC Infectious Diseases 2011, 11:3
http://www.biomedcentral.com/1471-2334/11/3
Page 3 of 12Immigration TB epidemiology of surveyed countries
For all of the countries studied the mean incidence rate
for all forms of TB in 2006 was 8.7/100,000 (95% CI
(5.9 - 11.4)) and for smear positive PTB, the mean inci-
dence rate was 3/100,000 (95% CI (1.7 - 4.3)). Italy,
Japan and Spain did not have formalized TB screening
programs for migrants. A significant difference was
noted between the mean incidence rates of all forms of
TB, 7.0/100,000 (95% CI (4.8 - 9.2)) in countries with a
screening program compared to 15.9 per 100,000 (95%
CI (11.3-20.6)) in countries with no screening program
(p = 0.002). A significant difference was also noted
between the mean incidence of smear positive pulmon-
ary TB of 2.3 per 100,000 (95% CI (1.1-3.5)) for coun-
tries with a screening program compared to the mean
incidence of 6.0 per 100,000 (95% CI (3.5-8.5)) for coun-
tries with no screening program (p = 0.012). The foreign
born constituted a mean of 58% of the TB cases
reported in all of the surveyed countries. A significant
difference was noted when the foreign born proportion
of all cases was compared between countries that had a
TB screening program and those that did not have a TB
screening program (65.2, 95% CI (55.6 - 74.9), 25.1, 95%
CI (4.9 - 45.19), p = 0.002).
Objectives of the Immigration Medical Exam (IME) in
relation to TB
The primary objective of all screening programs was to
identify active PTB. However, in Israel, and Sweden
screening included the routine detection of LTBI using
tuberculin skin testing (TST). In Canada, Australia and
the U.S., individuals deemed to be at greater risk of
inactive PTB were identified on the basis of the CXR
findings.
Table 2 Country TB rates per 100,000 population for 2006
Country Incidence of all forms of TB as
reported by the country
Incidence of smear positive PTB*
as reported by the country
Foreign born proportion
of all cases of TB%
% of cases for which country
of birth status is known†
TB screening program present
United
States
4.6 2‡ 57
Germany 6.6 1.7 43.3 97
France 8.5 3.3 45
Canada 5 2 64 97
United
Kingdom
15‡ 7‡ 73
Australia 5.8 3 81.6
Israel 5.5 1 82.3
Switzerland 7 2 78 75
Jordan 6.4 2 38
New
Zealand
8.6 2.6 70 85
Netherlands 6.2 1.3 63
Norway 6.3 1 81
Sweden 5.5 1.2 72
Mean 7.0 2.3 65
TB screening programs absent
Japan 22‡ 10‡ 4
Spain 18.3 5 25 76
Italy 7.5 3 46.2
Mean 15.9 6.0 25
*PTB - pulmonary tuberculosis
†Number represents the percent of individuals with TB where the country of origin for the case was known
‡ World Health Organization (WHO) 2006 rates[54], country reported rates may differ from estimates prepared by the WHO which uses various epidemiological
models to estimate rates.
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examination (IME) screening
Funding for the screening TB program structure was
provided by the government across all countries sur-
veyed. All countries that screen for TB in the country of
origin require the immigrant applicant to pay for any
tests including the CXR. All countries surveyed, except
for the United States, paid for the treatment of an active
case detected through screening in the host country.A l l
stated that the detection of active TB did not affect the
overall outcome of the immigration application. How-
ever, the immigration process was interrupted or
delayed until the individual successfully completed TB
treatment if active TB was detected on screening.
Immigration TB screening effectiveness
France, Jordan, the Netherlands and Switzerland routi-
nely documented the yield of active PTB detected
through the screening program, with rates in 2006 ran-
ging from 153/100,000 persons screened in Jordan to a
rate of 70/100,000 in France (Table 3). Australia’se s t i -
mated rate in 2006 was 43/100,000 while New Zealand’s
was 221/100,000. While the Canadian estimate for 2006
was 101 per 100,000, precise counting of cases in 2008
resulted in a rate of 54/100,000.
Demographic characteristics of those subject to
immigration TB screening
Australia, Canada, France, the Netherlands, New Zeal-
and, Norway, United Kingdom (U.K.) and the U.S.
screen all categories of those applying for permanent
residence. This includes immigrants, asylum seekers and
refugees (Table 4). Germany, Sweden and Switzerland
screen only asylum seekers and for Germany also re-set-
tlers. Israel’s program focuses on the geographical origin
of migrants rather than the type of migrant, although
any migrant who is coming for the purposes of work in
Israel is screened in the country of origin.
Major differences in approach were noted among
countries surveyed in regards to those arriving for tem-
porary periods of residence (Table 4). Germany, Sweden,
Switzerland, the U.K. and the U.S. do not screen tem-
porary residency applicants. Australia, Canada, France,
Israel, Jordan, New Zealand, Netherlands and Norway
do screen temporary migrants who are staying longer
than 3-6 months. Australia uses the country of origin
TB prevalence rate to determine which temporary
migrants they will screen (e.g. screen if the TB rate
exceeds 100/100,000 population and the migrant will
stay >1 month). In the U.S., individuals who are not
immigrants or refugees, namely, students, workers, visi-
tors and illegal migrants are not routinely screened for
TB as part of the immigration screening program [23].
Occupation
Several countries including Australia, Canada, and New
Zealand screen applicants working in occupations asso-
ciated with risks of work-related disease transmission.
These include health care providers, teachers and child-
care providers. In Canada, foreign nationals are required
Table 3 Number of immigrants and refugees that had TB immigration screening done, the absolute number and
calculated rates of active TB cases detected in 2006*
Country Number of
immigrants and
refugees screened
Absolute number of active cases
detected†
Calculated number of active cases detected
per 100,000
Calculated percent
yield
(absolute/total ×
100)
In
country
Out of
country
Canada* 111,280 407,206 278 53.6 0.05%
France 205,713 143 70 0.07%
Jordan 212,428 43,414 391 153 0.15%
Netherlands 63,268 67 105 0.11%
Switzerland 8,995 11 122 0.12%
Estimates
Australia 200,000 500,000 400 80 0.08%
New
Zealand
126,213‡ 279‡ 221 0.22%
*2008 provisional data for Canada.
† The definition of an active cases included: smear AFB positive and or culture TB positive.
‡ The number represents both in and out of country migrants and those applicants who were staying over 12 months and submitted full medical. Applicants
who may have been screened with only a CXR and no medical (those people from high-incidence countries who are staying for more than 6 months but less
than a year) would not have been included and the 279 represents the number of people who were defined as having an unacceptable standard of health out
of the people who submitted full medical certificates likely to mean they had TB however this data was not available.
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they are seeking to work in an occupation in which the
protection of public health is essential whatever the
length of stay in Canada or country of origin. In
Norway, examination is required for persons who have
arrived from, or who have spent at least three months
in, a country with a high prevalence of TB require pre-
employment screening.
Location of screening
Immigration screening for TB may take place in three
locations:
(1) Pre-departure screening commonly in the country
of origin
(2) On arrival screening commonly occurs at the point
of entry into the host country and at airports and other
centers were migrants transit
(3) Post arrival screening occurs once the migrant has
left the airport or centers used for transitioning. It
includes post arrival surveillance or follow up of identi-
fied cases. Post arrival screening may be active where
the foreign-born are required to undergo examination
because of their immigration status. Alternatively, it may
by passive and undertaken during routine health care as
recommended by national guidelines.
Countries receiving a high number of immigrants and
having a national PTB incidence rate of < 15/100,000
population (Table 1) tended to screen applicants in the
country of origin as compared to countries that did not
form part of this list but were included in our study
(Table 5). Countries accepting a lower number of
migrants tended to screen after the migrant had arrived.
Most asylum seekers were screened sometime after arri-
val. However, some countries utilizing reception or
holding centers for those seeking asylum undertook
screening immediately on arrival at the center. Australia,
Canada and the U.S. screened convention refugees in
the country of origin. The U.K. had several possible
points of screening (pre/at/post entry) depending on
country of origin, route in to the U.K. and migration
status. Most survey respondents from countries that
did pre-departure screening identified the lack of
Table 4 Type of migrants that get screened
Country Permanent residency application Temporary residency application
Immigrant Asylum
seekers
Convention
refugee
Visiting Students Temporary Workers/Visitors Specific
United States ++ + –– –
Germany ++ - –– –
France + + + > 3 months > 3 months –
Canada + + + > 6 months* > 6 months* Occupation†
United Kingdom + + + > 6 months > 6 months –
Australia + + + > 1 months
(>100/100K)
> 3 months
(> 60/100K)
> 12 month
(< 20/100K)‡
Nursing, dental, child care
worker
Occupation†
Israel –– – – + –
Jordan ++ – > 3 months > 3 months Adoptee
Additional
Countries
Norway + + + > 3 months > 3 months Adoptee
New Zealand + + + > 6months (with risk
factors)**
> 12 months (all)
> 6months (with risk factors)**
> 12 months (all)
–
Switzerland – + –– – –
Sweden – + –– – –
Netherlands + + + > 3 months > 3 months Adoptee
+ = YES and – = NO.
*Temporary residents who will stay in Canada for more than 6 months and who have spent >6 consecutive months in a high incidence countries are also
screened.
‡ In Australia, countries with TB rates < 20/100,000 get a CXR if coming for > 12 months and if ≥ 20/100,000 than a CXR is done if coming for more than 3
months >.
** New Zealand screens all applicants intending to stay for more than 12 months for TB. It also screens applicants intending to stay more than six months if
there are risk factors present (ie. they hold a passport for a country not considered to be low incidence of TB, or if, in the five years prior to application, they
have spent three months or more in any such country/ies).
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a major limitation of screening abroad.
Screening for active TB disease
Chest radiograph (CXR)
Differences among countries existed in the type of phy-
sician who interpreted the CXR. These ranged from
general practitioners who are designated medical practi-
tioners (DMP) or panel doctors to TB specialists, respir-
ologists or radiologists. The countries that carry out
pre-departure screening had systems in place for local
radiologists to read the CXR. In Australia all x-rays are
read by DMPs from all high risk countries (total TB
incidence >100/100 000 general population ) and panel
doctors from others are audited through desk top
reviews by DMPs in Sydney. Thus, all panel radiologists
are supervised by DMPs. Only Israel had a centralized
method of reading CXRs where two radiologists read all
of the immigration screening CXRs. In Canada, CXRs
are examined by a local radiologist in the country of ori-
gin and then another assessment is done by a physician
hired by the Canadian government to perform that task
or by a Canadian Immigration Medical Officer. Canada
is the only country surveyed to use a scoring system to
further quantify the risk of TB disease. The 18 factor
ascending scale is designed to detect active and inactive
PTB [14].
Respiratory secretion testing
All countries indicated that they used both acid-fast
bacilli (AFB) smear and culture in applicants with
abnormal CXRs and/or clinical signs and symptoms of
TB. Depending on country and location, cultures may
be obtained from sputum, bronchial aspiration or gastric
lavage. Technical instructions and guidance vary by
country and these guidelines are periodically modified.
For example the U.S. is in the process of implementing
new TB guidelines (2007 Techncial Instructions for
Tuberculosis Screening and Treatment) requiring regu-
lar collection of sputa for microscopy and culture and
the routine use of TSTs for those who do not require a
radiograph [24]. Historically, laboratory investigation
was only required for those suspected of having active
PTB. Drug susceptibility testing is now required for all
positive cultures.
TST
The U.S. (where the 2007 TB TI has been implemented)
use the TST for screening children for active TB disease.
The Netherlands use the TST to screen all unvaccinated
children for active TB disease.
Screening for LTBI
TST
Israel, Norway and Sweden use the TST to diagnose
LTBI in migrants entering the host country. While most
c o u n t r i e sd on o ts c r e e nf o rL T B Ia sp a r to ft h ei m m i -
gration screening program, they do recommend the use
of the TST to screen high risk immigrants in the pri-
mary care setting after the immigration process is com-
pleted. The reasons for not using the TST [25] include:
(1) false positives due to BCG (bacille Calmette-Guérin)
Table 5 Point of screening
Country Immigrants Refugees/Asylum seekers
Country of origin On arrival After arrival Country of origin On arrival After arrival
United States + – ++ – +
Germany –– – –– +
France + – + –– +
Canada + –– + – +
United Kingdom + + +¥ +
Australia + –– + – +
Israel +* –– – ––
Jordan +†– + –– +
Additional Countries
Norway – ++ – + –
New Zealand + – ++ - +
Sweden –– + –– +
Switzerland –– – –+ –
Netherlands –– + –– +
+ = YES and – =N O
* Ethiopia is the only country where Israel is performing CXRs and TST (1
st step) for screening in the country of origin
†Jordan does screen applicants from Sri Lanka, Indonesia and the Philippines abroad
¥ For programme refugees
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teria, (2) very large number of TST positive applicants,
(40-50% of adult immigration applicants have lived for
20 years or more in high TB incidence countries [14]),
(3) low reactivation risk among many with a positive
TST and (4) poor adherence to current LTBI treatment
regimes in most programs [26].
CXR for detecting inactive PTB as a form of LTBI
In Canada, inactive PTB cases are defined by a combina-
tion of radiological and laboratory criteria. In the
absence of clinical symptoms, abnormalities compatible
with PTB that are radiologically stable for more than
6 months are considered to represent inactive PTB.
Similar conclusions result from three-month radio-
g r a p h i cs t a b i l i t yi nt h ep r e s e n c eo fn e g a t i v es m e a r sa n d
cultures [14]. In Canada and Australia, applicants who
have inactive PTB detected on CXR are put on medical
surveillance or receive a health undertaking to attend
for review and follow up after arrival.
Interferon Gamma Release Assays (IGRA) for detection
of LTBI
Norway and the U.S., where the 2007 TB TI are in use,
are the only surveyed countries that have adopted the
IGRA as part of the national immigration TB screening
program. A study in Norway demonstrated that use of
an IGRA would have reduced the number of asylum
seekers needing further follow up by 43% [27]. Although
this would not affect the number of applicants referred
for screening, use of the IGRA could improve the selec-
tion of persons to refer for further evaluation.
Post arrival immigration medical surveillance
Managing inactive PTB is an important component of
the immigration screening programs of some countries.
Known as medical surveillance, a health undertaking or
medical referral, it involves post-arrival medical evalua-
tion in order to consider treatment to prevent progres-
sion of inactive PTB to active disease. The process owes
its origin and name to the practice of regular clinical
review of TB patients to watch for disease reactivation
before preventive treatment for inactive PTB was avail-
able. It does not represent epidemiological surveillance
of the disease.
In Canada, inactive PTB is diagnosed in 2% of all
immigration applicants [14] and associated with a five
time higher risk of reactivation when compared to appli-
cants with a normal CXR [18]. In some studies in
Canada, 1.5-2.8% of persons referred for medical surveil-
lance were diagnosed with active TB at their first medi-
cal evaluation [28,29]. Eight countries including France,
Germany, Netherlands, New Zealand, Norway, Sweden,
Switzerland and the U.S. did not report formal programs
to review those with inactive PTB or latent infection in
the post arrival phase of the immigration process (Table
6). Although the U.S. does not have a legally binding
process for follow-up evaluations or surveillance of
arriving persons suspected of having TB, they are in the
process of fully implementing an Electronic Disease
Notification (EDN) system that transmits information
on arriving immigrants and refugees with a TB classifi-
cation to receiving health departments. Prior to EDN,
there was a paper-based system for notifying receiving
health departments of arrival for all refugees and all
immigrants suspected of having TB. Two countries,
Australia and the Netherlands, had collected data on
compliance with the first follow up visit measured at
80% and 59% respectively.
Discussion
The majority of the countries participating in the study
utilize some sort of immigration screening program.
This may be related to the use of immigration as a pol-
icy of nation building as well as epidemiological evi-
dence indicating a greater proportion of disease in
foreign-born or migrant populations. In countries with-
out routine screening programs the relatively low pro-
portion of disease in the foreign-born along with low
numbers of migrants may be reasons routine screening
is not undertaken [30-34]. The primary objective of all
TB screening programs is to detect active TB. Therefore,
an important measure of the effectiveness of the pro-
gram is the prevalence of active TB among those
screened. While other indicators may be measured to
assess TB immigration screening (migrant satisfaction
and understanding of the program, adherence to the
program by health professionals and migrants and the
cost effectiveness of programs) they were not collected
in this study. Our study demonstrates that the yield of
active cases in terms of rates is several times the inci-
dence of active disease in all of the host nations doing
the screening where data were available (Table 3). It is
important to note that several countries did not limit
TB screening to applicants from high TB incidence
countries. The yield of active pulmonary TB may be
improved through more targeted application of screen-
ing practices, either based on countries of previous resi-
dence and/or risk factors for progression of LTBI to
active disease [5,11,18,35-37]. Direct comparisons
among countries must be made with caution as the
characteristics and health determinants of persons
screened vary by both by country of origin and by
destination.
The location at which screening takes place varies
between countries. Factors that determine screening loca-
tion include domestic law, the annual number of immi-
grants admitted and cost of operations. For receiving
countries, advantages of pre-departure screening include
the prevention of the arrival of individuals with active or
Alvarez et al. BMC Infectious Diseases 2011, 11:3
http://www.biomedcentral.com/1471-2334/11/3
Page 8 of 12infectious disease. The major challenge in pre-departure
screening noted across all countries is the difficulty of
quality assurance of medical examinations and laboratory
tests done overseas and fraudulent documents.
There is no standard determination of which migrant
populations should be subject to immigration screen-
ing for TB. Some nations screen all applicants. Others
only screen those seeking permanent residence or
those staying for extended periods. Some nations
screen on the basis of intended occupation. Some
countries base the requirement for screening on the
level of disease at the migrant’s place of origin. In such
countries, significant variability exists in the TB inci-
dence rate of the source country, which will trigger an
examination. Variations in the triggers for screening
(origin, migrant class, occupation), migrant demogra-
phy (source, age, duration of stay), nature of the immi-
gration movement (refugee, asylum seeker, migrant
worker etc.) make the comparison of national screen-
ing programs a challenging task. More detailed studies
comparing disaggregated standardized information will
be important in evaluating the impact and effect of
national differences in screening.
As noted a limited number of nations are currently
using an IGRA as a confirmatory test for all positive
TSTs (two-step approach). The two-step approach
improves the one-step approach (IGRA only) by pre-
venting the loss of applicants who had a false negative
IGRA result [38-40].
The expanded use of IGRAs suggested by recent stu-
dies does have limitations. Many applicants may be
identified as having a positive test however many of
them may not go for the follow up or agree to treat-
ment. For countries that do pre-departure screening,
logistical and operational aspects may be pose significant
challenges to implementing the use of IGRAs in devel-
oping nations due to a lack of laboratory support and
quality control.
All radiological screening programs are subject to
interpretation error. Experience and the number of
interpreters has been shown to affect interpretation.
Standardized interpretation should be a goal of all
screening programs using CXRs. Studies have [41]
demonstrated that experience in reading CXRs for pos-
sible active TB among asylum seekers can play a signifi-
cant role in the reproducibility of the reading. Although
not done within an immigrant TB screening program, it
has been suggested that [42] TB specialists had better
accuracy in detecting TB related abnormalities. If films
are digitized at each site and transmitted electronically
to a central reading site, all interpretation can be done
by a designated panel of TB radiology experts with an
increase in the accuracy of diagnosing active and inac-
tive PTB.
The greatest risk for the development of TB occurs in
the first year after entering the host nation and then the
risk decreases over time [43-45]. However, even though
the risk diminishes over time, it is still higher than the
Table 6 Post arrival immigration surveillance
Country Refugee
Center
Follow up post
arrival
Compliance with first follow
up
Consequences to not coming to follow up
United States No No ––
Germany‡ Yes No ––
France Yes No – Residency permit not issued
Canada Yes Yes 49% Reflects negatively on applicant immigration
success
United
Kingdom
Yes¥ Yes Not known No
Australia No Yes 80% No
Israel Yes †– –
Jordan No Yes Not known Residency permit not issued
Additional Countries
Norway Yes No ––
New Zealand Yes No ––
Sweden Yes No ––
Switzerland Yes No ––
Netherlands No Yes 59%* No
*compliance data for non refugee immigrant only[55]
† Migrants usually stay up to 1-2 years in the absorption centers
‡Follow up post arrival is done for persons with suspicious findings, but decentralized and the information is not collected systematically at central level
¥ Asylum seeker initial accommodation rather than refugee center
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even 10-20 years later [46-48]. Furthermore, the higher
the TB burden in the country of origin, the higher the
probability of disease following migration into the host
country [49]. The attention on the identification of
active disease at the time of immigration provided by all
countries with screening programs will assist in the
management of migration-related TB. However, without
a corresponding program to manage LTBI and non-
infectious TB in new arrivals, immigration screening will
continue to have a limited impact on TB in the foreign
born.
Origin, length of proposed stay and occupation all
influenced screening requirements and varied among
countries. Temporary residents can represent a signifi-
cant source of TB [23,50].
International university/college students from high
incidence countries can potentially be an important
source of TB into the host nation. The literature suggest
that foreign born students may contribute a significant
amount of TB in a population and should thus be
screened for LTBI after arrival at the school [50]. In the
USA LTBI screening with TSTs of international stu-
dents in one scholastic year found 35% of students to
have a positive TST, of which 80% were successfully
treated [51].
Limitations of the study
Subtle cultural and political differences among countries
are sometimes difficult to measure and thus report.
Accuracy of the information reported is dependent on
the participants. Effort was made to include only experts
from each country. The accuracy of the information is
also time sensitive and subject to change since it is
always evolving. The survey was designed to compare
particular aspects of the Canadian TB immigration
screening program with other nations’ programs. Other
aspects that were present only in other countries may
not have been included in the study.
Common Goals - Partnerships between immigrant source
and host countries
Several of the high immigration, low TB incidence
countries did pre-departure screening in the countries
of origin. Each receiving country had its own protocol
and arrangements with (sometimes the same) labora-
tories, radiology services and examining physicians in
the source countries. Program efficiency and effective-
ness could result from the pooling of resources such as
laboratory, radiology and examining physicians, (e.g., the
practice of Australia and New Zealand sharing panel
physicians). High standards of radiological and labora-
tory diagnosis are required by many screening countries.
These services may be in short supply in high incidence
regions. The support and improvement of TB services
and management capacity in migrant source regions by
migration destination countries which require immigra-
tion medical screening has both domestic and interna-
tional benefit. More robust TB services in high TB
incidence regions mutually supports TB prevention in
migrants from those areas and in future host countries.
For example, as part of the U.S. implementation of
their 2007 TB immigration screening requirements, the
Centers for Disease Control and Prevention (CDC)
helped develop laboratory and treatment programs to
support their new culture and directly observed treat-
ment requirements. Since implementation began, new
TB laboratories (performing cultures and drug sensitiv-
ity testing) began to operate in Kenya, Mexico, Nepal,
Thailand, and Vietnam. Existing laboratories have
expanded greatly in the Dominican Republic and the
Philippines. As part of this program, the CDC is trying
to engage in-country TB organizations, such as National
Tuberculosis Programs, so that the TB control infra-
structure used for U.S. immigration applicants will also
benefit the rest of the nation’s population.
Conclusions
As presented by others [3,52,53], immigration TB control
needs to expand to a global level to achieve a significant
decrease in the number of immigrants from high TB inci-
dence countries who are found to have TB on immigra-
tion screening or to develop it soon after arrival. Host
nations should invest in targeted TB programs in devel-
oping countries that form the bulk of the TB entering the
country. Such an approach was shown to be cost effective
in a U.S. based model [52]. This global approach to TB
immigration must be based on a collaboration between
TB screening immigration programs and the national TB
programs in the countries of origin so that both immi-
grant source and receiving countries benefit.
In a globalized, mobile world, a case can be made for
recommending that immigration medical screening
should be a routine consideration for all national TB
control programs. It is anticipated that immigration TB
screening programs for high immigration low TB inci-
dence countries will vary with national legislation,
resource availability and public health risk management
practices. Advances in medical science, diagnostic tech-
nology and therapeutic options continue to provide new
considerations through which effectiveness of screening,
both in terms of cost and health outcomes can be evalu-
ated and improved. Technologies and resource alloca-
tion will vary by nation according to national priorities
but targeting high risk populations remains an impor-
tant feature of any screening program.
Improved screening of temporary residents and inter-
national university/college students may enhance
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screening of high risk migrants for LTBI with IGRA is a
promising approach and further research is necessary.
The digitization of CXRs which facilitates centralized
interpretation by those with extensive TB experience is
another area of interest in low incidence nations and may
improve the accuracy of radiological screening. Advances
in technology are important however to be effective these
programs need to be integrated with domestic TB control
programs and linked to international partners to ensure
quality standards and coordinated patient care across
borders are components of screening programs. Lastly,
screening programs should adhere to international stan-
dards in terms of access to care and treatment, ethics and
privacy data management.
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